Sino-US firm MicuRx Pharmaceuticals Inc. (SHA: 688373) has announced that it has received clinical trial approvals for its novel anti-microbial agent MRX-4 in combination with contezolid (MRX-I) as a sequential treatment for diabetic foot infections. The approvals span several countries, including the United Kingdom, Turkey, Georgia, Argentina, and Chile.
Both MRX-4 and contezolid are in-house developed new-generation oxazolidinone antibiotics. Contezolid received approval in China in June 2021 for the treatment of complex skin and soft tissue infections. MRX-4, the pro-drug version of contezolid (MRX-1), is a potent oxazolidinone antibiotic effective against Gram-positive pathogens.
The MRX-4/contezolid combination has previously been approved for use as a sequential treatment for infections caused by drug-resistant Gram-positive bacteria. In addition to the recent approvals, clinical trials for this combination have also been authorized in the USA, China, France, Greece, Hungary, Italy, Latvia, Lithuania, Portugal, Spain, Estonia, Israel, Bulgaria, Slovakia, Croatia, Poland, and Brazil.-Fineline Info & Tech
